Quant Biomarkers AG

Quant Biomarkers AG is developing RenoRisk™, a urine-based biomarker panel for early detection of chronic kidney disease (CKD), up to five years before current standard diagnostics. CKD affects 1 in 10 people globally, yet over 90% remain undiagnosed in early stages, when intervention is most effective. Early kidney impairment is strongly linked to increased morbidity and mortality, particularly through heart failure and cognitive decline, within the broader cardio–kidney–metabolic (CKM) syndrome. RenoRisk addresses this diagnostic gap by enabling early, accessible, and precise detection of kidney involvement. The test is designed for standard laboratories and can later be adapted into a point-of-care solution for primary care, specialty, and longevity clinics.